Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 16/20 | 0.71 |
| ▸ | BTK | Q06187 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.47 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15935588 | 0.86 | SYK (0.88) | SYKBTKKCNH2MAPK3MAPK1 | |
| SCHEMBL14839090 | 0.86 | SYK (0.88) | SYKBTKKCNH2MAPK3MAPK1 | |
| SCHEMBL14839236 | 0.83 | SYK (1.00) | SYKKCNH2 | |
| SCHEMBL14838950 | 0.82 | SYK (0.85) | SYKBTKKCNH2MAPK3MAPK1 | |
| SCHEMBL16255416 | 0.81 | SYK (0.71) | SYKBTKKCNH2MAPK3MAPK1 | |
| SCHEMBL16253408 | 0.79 | SYK (1.00) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL15910711 | 0.79 | SYK (0.83) | SYKBTKKCNH2MAPK3MAPK1 | |
| SCHEMBL18283777 | 0.78 | BTK (0.66) | SYKBTKKCNH2MAPK3MAPK1 | |
| SCHEMBL18283774 | 0.78 | BTK (0.66) | SYKBTKKCNH2MAPK3MAPK1 | |
| SCHEMBL14838965 | 0.76 | SYK (0.88) | SYKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145414-B2 | 1,2,4-triazine-6-carboxamide derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-29 | — | — | US | disclosed |
| US-20140343038-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
| WO-2013047813-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | 大鵬薬品工業株式会社 (JP) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343038-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | SYK, BTK, JAK2 | SYK 1/4885BTK 2/4885KCNH2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.